Mladen Jergovic

Mladen Jergovic

Auto-generated profile, based on publicly available information

Mladen Jergovic

Department of Immunobiology, University of Arizona College of Medicine-Tucson

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 February 2018 in European Journal of Pediatrics
Verified
Journal Article
Closed access
PDF file
AMAna Savic Mlakar
Ana Savic Mlakar
IHIva Hojsak
Iva Hojsak
MJMladen Jergović
Mladen Jergović
SČSamir Čimić
Samir Čimić
KBKrešo Bendelja
Krešo Bendelja

25 February 2022 in medRxiv
Verified
Preprint
Open access
PDF file
MWMakiko Watanabe
Makiko Watanabe
MJMladen Jergovic
Mladen Jergovic
LDLisa Davidson
Lisa Davidson
BLBonnie J LaFleur
Bonnie J LaFleur
YCYvonne Castaneda
Yvonne Castaneda
JNJanko Nikolich-Žugich
Janko Nikolich-Žugich
SUMMARY: HIV-positive patients whose viral loads are successfully controlled by active antiretroviral therapy (ART) show no clinical signs of AIDS. However, their lifespan is shorter compared to individuals with no HIV infection and they prematurely exhibit a multitude of chronic diseases typically associated with advanced age. It was hypothesized that immune system aging may correlate with, and provide useful biomarkers for, this premature loss of healthspan in HIV+ subjects. Here, we tested whether the immune correlates of aging, including cell numbers and phenotypes, inflammatory status and control of human cytomegalovirus (hCMV) in HIV-positive subjects on long-term successful ART (HIV+) may reveal increased “immunological age” compared to healthy, age-matched cohort (HC) in participants between 50 and 69 years of age. Specifically, we expected that younger HIV+ subjects may immunologically resemble older individuals without HIV. We found no evidence to support this hypothesis. While T cells from HIV+ participants displayed different expression of several differentiation and/or inhibitory/exhaustion markers in different T cell subpopulations, aging by a decade did not pronounce these changes. Similarly, while the HIV+ participants exhibited higher T cell responses and elevated inflammatory marker levels in plasma, indicative of chronic inflammation, this trait was not age-sensitive. We did find differences in immune control of hCMV, and, more importantly, a sustained elevation of sCD14 and of proinflammatory CD4 and CD8 T cell responses across age groups, pointing towards uncontrolled inflammation as a factor in reduced healthspan in successfully treated older HIV+ patients.